+141.9%
DKNG vs GSK
+58.2%
+83.7%
-85.7%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | +0.2% | -1.0% | +1.3% | +0.5% |
| 7D | -2.0% | -5.4% | +3.4% | -0.3% |
| 30D | -6.4% | -4.6% | -1.8% | -5.1% |
| 3M | -17.6% | -5.1% | -12.5% | -16.4% |
| 6M | -5.7% | -11.4% | +5.7% | -2.6% |
| YTD | -31.2% | +0.7% | -31.9% | -32.3% |
| 1Y | -48.1% | +23.0% | -71.1% | -52.7% |
| 3Y | -25.6% | +48.0% | -73.5% | -40.1% |
| 5Y | -62.0% | +48.2% | -110.2% | -70.6% |
| All | +141.9% | +58.2% | +83.7% | +85.2% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling